Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers

Immune checkpoint inhibitors (ICIs) are highly concerned in the treatment of non-small cell lung cancer (NSCLC), represented by inhibitors of programmed death protein 1 (PD-1) and its ligand (PD-L1), and inhibitors of cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). The introduction of immunoth...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Xinyu Wu, Yi Fung Chau, Hua Bai, Xiaofei Zhuang, Jie Wang, Jianchun Duan
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Frontiers Media S.A. 2023-01-01
Saila:Frontiers in Oncology
Gaiak:
non-small cell lung cancer
neoadjuvant therapy
immune checkpoint inhibitors
PD-L1
circulating tumor DNA
tumor mutation burden
Sarrera elektronikoa:https://www.frontiersin.org/articles/10.3389/fonc.2022.1099304/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1099304/full

Antzeko izenburuak